Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 596-599, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-271953
ABSTRACT
Homoharringtonine(HHT) is an alkaloid with anti-tumor activity, having a good therapeutic effect on chronic myeloid leukemia(CML), and its toxicity is much lower than other anti-cancer drugs. However, the remarkable therapeutic efficacy of imatinib on CML treatment made HHT to be forgotten gradually. Today, the omacetaxine mepesuccinate, a semisynthetic form of HHT, display a good clinical response to TKI-resistant CML patients. Therefore, the HHT again attracts more attention from the medical field. Here, the clinical effects of HHT on IM-resistant CML patients and its mechanism are briefly reviewed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS